Nedosiran clinical trials
Also written DCR-PHXC.
How each study uses nedosiran is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the nedosiran studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 29 Sept 2023 · RIVFLOZA · NDA 215842 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
6 studies that test it; most in 2019 (2)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company (5) · Novo Nordisk A/S (1)
Studies
Open first, then newest update. How each study uses nedosiran is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRDRecruitingPhase 2Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyNCT04580420Written as DCR-PHXCHow we know
- Long Term Extension Study in Patients With Primary HyperoxaluriaActive, not recruitingPhase 3Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyNCT04042402Written as DCR-PHXCHow we know
- Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal FunctionCompletedPhase 2Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyNCT05001269Written as nedosiranHow we know
- Study of DCR-PHXC-101 in Normal Healthy Volunteers and Patients With Primary HyperoxaluriaCompletedPhase 1Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyNCT03392896Written as DCR-PHXCHow we know
- Study to Evaluate Safety, Tolerability, PK and PD of DCR-PHXC in PH Type 3 PatientsCompletedPhase 1Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyNCT04555486Written as DCR-PHXCHow we know
- A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2CompletedPhase 2Novo Nordisk A/SNCT03847909Written as DCR-PHXCHow we know
Codes
What other systems call nedosiran · ClinicalTrials.gg INT001939
- MeSH (NLM) C000723113nedosiranConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 13U9R5J3WLNEDOSIRANConfirmed FDA, Wikidata
- Wikidata Q123420884nedosiranConfirmed FDA, Wikidata
- NCI Thesaurus C175828NedosiranOne source FDA
- DrugBank DB17635One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000723113 | nedosiran | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 13U9R5J3WL | NEDOSIRAN | Confirmed FDA, Wikidata |
| Wikidata | Q123420884 | nedosiran | Confirmed FDA, Wikidata |
| NCI Thesaurus | C175828 | Nedosiran | One source FDA |
| DrugBank | DB17635 | — | One source Wikidata |
Also registered as nedosiran sodium (UNII EGR9KYM536).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.